Research Topics
Species | R W PriceSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous systemRichard W Price
Department of Neurology, University of California San Francisco, San Francisco, California, USA
J Neurovirol 10:44-51. 2004..The proportionally greater increase in CSF HIV after treatment interruption indicates that CSF HIV infection is often more effectively suppressed by combination antiretroviral therapy than is systemic infection...- Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatmentAsa Mellgren
Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
Antivir Ther 10:701-7. 2005..We conclude that the central nervous system (CNS) is usually not a 'sanctuary site', difficult to reach with combination antiretroviral treatment... 
Antiretroviral therapy and central nervous system HIV type 1 infectionRichard W Price
Department of Neurology, University of California San Francisco, San Francisco General Hospital, 1001 Potrero Avenue, San Francisco, CA 94117, USA
J Infect Dis 197:S294-306. 2008..With better control of these severe disorders, attention has turned to the possible consequences of chronic silent infection and the issue of whether indolent, low-grade brain injury might require earlier treatment intervention...- Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 originRichard W Price
Department of Neurology, University of California, San Francisco, CA, USA
Antivir Ther 13:369-74. 2008..Here, we define cerebrospinal fluid (CSF) enfuvirtide pharmacokinetics and present a case illustrating the use of enfuvirtide as a probe to trace the origins of CSF HIV-1 quasispecies... 
Targeting chronic central nervous system HIV infectionRichard W Price
Department of Neurology, University of California San Francisco, San Francisco General Hospital, San Francisco, CA, USA
Antivir Ther 17:1227-31. 2012..Although there are important questions regarding the theoretical underpinnings of both this score and its application, the findings present a novel slant on therapy...- The cerebrospinal fluid proteome in HIV infection: change associated with disease severityThomas E Angel
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA, USA
Clin Proteomics 9:3. 2012..abstract:.. - Amyloid and tau cerebrospinal fluid biomarkers in HIV infectionMagnus Gisslen
Department of Infectious Diseases, University of Gothenburg, Sahlgrenska University Hospital, SE 416 85 Gothenburg, Sweden
BMC Neurol 9:63. 2009..Because of the emerging intersections of HIV infection and Alzheimer's disease, we examined cerebrospinal fluid (CSF) biomarkers related of amyloid and tau metabolism in HIV-infected patients... - The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?Magnus Gisslen
Department of Infectious Diseases, Sahlgrenska University Hospital, University of Gothenburg, Sweden
BMC Infect Dis 11:356. 2011..This includes a new disorder that has been termed asymptomatic neurocognitive impairment (ANI)... - Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatmentSerena S Spudich
Department of Neurology, University of California, San Francisco, USA
BMC Infect Dis 5:98. 2005..Because of its proximity to and shared barriers with the brain, cerebrospinal fluid (CSF) provides a useful window into and model of human CNS HIV infection... - Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infectionLars Hagberg
Department of Infectious Diseases, Sahlgrenska University Hospital, University of Gothenburg SE 41685 Sweden
AIDS Res Ther 7:15. 2010.... - Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot studyJ C Probasco
Department of Neurology, University of California San Francisco, CA, USA
Neurology 71:521-4. 2008..Based on the potential immunomodulatory and antiviral properties of HMG-CoA reductase inhibitors (statins), we examined the effect of atorvastatin on CSF HIV-1 infection and associated CSF abnormalities in a small pilot study... - Biomarkers of HIV-1 CNS infection and injuryR W Price
Department of Neurology, University of California, San Francisco, CA, USA
Neurology 69:1781-8. 2007..This review considers the rationale and prospects of these approaches... - Minocycline fails to modulate cerebrospinal fluid HIV infection or immune activation in chronic untreated HIV-1 infection: results of a pilot studyEmily L Ho
Department of Neurology1 University of California San Francisco, San Francisco, CA, USA
AIDS Res Ther 8:17. 2011..abstract:.. - Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infectionElizabeth Sinclair
Department of Medicine, University of California at San Francisco, San Francisco, CA, USA
J Acquir Immune Defic Syndr 47:544-52. 2008..To define the effect of antiretroviral therapy (ART) on activation of T cells in cerebrospinal fluid (CSF) and blood, and interactions of this activation with CSF HIV-1 RNA concentrations... - CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapyMarta Valle
Department of Biopharmaceutical Sciences, University of California San Francisco, USA
Brain 127:1047-60. 2004..The time course of therapy-induced changes links CSF QUIN to local infection and supports the action of antiviral therapy in ameliorating immunopathological brain injury and ADC... - Increased adhesion molecule and chemokine receptor expression on CD8+ T cells trafficking to cerebrospinal fluid in HIV-1 infectionBarbara L Shacklett
Gladstone Institute of Virology and Immunology, University of California, San Francisco, California, USA
J Infect Dis 189:2202-12. 2004..The central nervous system (CNS) is a recognized target for human immunodeficiency virus type 1 (HIV-1). CD8(+) T cells may mediate viral clearance from the CNS but also may contribute to immune-mediated neuronal damage... - Cerebrospinal fluid response to structured treatment interruption after virological failureR W Price
Department of Neurology, University of California San Francisco and San Francisco General Hospital, 94110 3518, USA
AIDS 15:1251-9. 2001..We report initial observations of cerebrospinal fluid (CSF) HIV-1 infection in five patients undergoing serial lumbar punctures (LPs) during STI undertaken following virological failure... - Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremiaPeter W Hunt
Positive Health Program, San Francisco General Hospital, San Francisco, CA 94110, USA
J Infect Dis 194:926-30. 2006..CCR5 inhibitors may thus be best strategically used before salvage therapy and before significant CD4 + T cell depletion... - HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapyJutta K Neuenburg
Department of Neurology, University of California, San Francisco, USA
J Acquir Immune Defic Syndr 31:171-7. 2002..Although combination therapies decrease overall mortality and prevalence of CNS opportunistic infections, these therapies may be less active in preventing direct HIV-1 effects on the brain... - Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapyJutta K Neuenburg
Gladstone Institute of Virology and Immunology, University of California, San Francisco, California 94158, USA
AIDS 19:1351-9. 2005..Although clinical brain disease is uncommon during combination antiretroviral therapy (ART), autopsy series indicate that HIV-infected brain tissue can contain high numbers of monocytes/macrophages despite ART... - Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failureSerena Spudich
Department of Neurology, San Francisco General Hospital, University of California, San Francisco, CA 94110 3518, USA
J Infect Dis 194:1686-96. 2006..To characterize the effect of partially suppressive combination antiretroviral therapy on cerebrospinal fluid (CSF) human immunodeficiency virus (HIV)-1 RNA levels and CSF inflammation... - T-cell activation and memory phenotypes in cerebrospinal fluid during HIV infectionJutta K Neuenburg
Department of Neurology, San Francisco General Hospital, General Clinical Research Center at the University of California, San Francisco, CA 94158, USA
J Acquir Immune Defic Syndr 39:16-22. 2005..In HIV-infection, activated CD4+ and CD8+ T cells in CSF were more abundant than in uninfected controls. As expected, combination antiretroviral therapy (ART) reduced T cell activation in CSF and blood... - HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremiaSerena S Spudich
Department of Neurology, University of California San Francisco, San Francisco, California, USA
J Infect Dis 191:890-8. 2005..Using an in vitro functional entry assay, we examined utilization of 2 principal coreceptors in cerebrospinal fluid (CSF) and plasma in 46 subjects... - HIV-producing T cells in cerebrospinal fluidJutta K Neuenburg
Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
J Acquir Immune Defic Syndr 37:1237-44. 2004..In HIV-1 infection, CSF white cell counts seem to contain a large number of uninfected cells. White cell counts and viral load in CSF may result from systemic inflammation and immune activation... - Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1--infected patients with and without AIDS dementia complexF Aweeka
Department of Clinical Pharmacy, University of California, San Francisco 94143 0622, USA
J Acquir Immune Defic Syndr Hum Retrovirol 20:39-43. 1999..To assess the penetration of the HIV-1 protease inhibitor, nelfinavir, into cerebrospinal fluid (CSF)... - A pilot study of the discontinuation of antifungal therapy for disseminated cryptococcal disease in patients with acquired immunodeficiency syndrome, following immunologic response to antiretroviral therapyJudith A Aberg
Department of Medicine, University of California San Francisco, San Francisco, CA, USA
J Infect Dis 185:1179-82. 2002..Disseminated cryptococcal disease can be cured by prolonged antifungal therapy in some patients with AIDS who experience sustained CD4 lymphocyte increases while receiving HAART... - Chemokine receptors, neural progenitor cells, and the AIDS dementia complexAimee W Kao
J Infect Dis 190:211-5. 2004 - Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapyArvid Edén
Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
J Infect Dis 196:1779-83. 2007..5 years, a substantial proportion of patients continue to show signs of macrophage/microglia activation and intrathecal immunoglobulin production in the CNS... - Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkersMagnus Gisslen
Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
J Neuroimmune Pharmacol 2:112-9. 2007..Careful analysis of this and other marker combinations promises more rational trial design and more rapid progress in managing CNS HIV infection and HRND using both antiviral and adjuvant treatment approaches... - Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapyAylin Yilmaz
Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
J Acquir Immune Defic Syndr 47:168-73. 2008.... - Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complexMagnus Gisslen
Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Goteborg, SE 416 85, Sweden, and Department of Neurology, St Vincent s Hospital, Sydney, NSW, Australia
J Infect Dis 195:1774-8. 2007..By contrast, no differences were found in CSF HIV-1 RNA or neopterin concentrations between the 2 groups. CSF NFL may prove to be a useful predictive marker for ADC... - The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestationsPaola Cinque
Clinic of Infectious Diseases, San Raffaele Scientific Institute, University of Milan, Italy
Ann Neurol 55:687-94. 2004..The overexpression of uPAR in the CNS of patients with ADC suggests that the uPA/uPAR system may contribute to the tissue injury and neuronal damage in this disease... - Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patientsLucette A Cysique
St Vincent s Hospital Clinical School, University of New South Wales, Darlinghurst, Sydney, Australia
J Acquir Immune Defic Syndr 39:426-9. 2005.... - Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infectionPaola Cinque
Clinic of Infectious Diseases, San Raffaele Hospital, Milan, Italy
J Neuroimmunol 168:154-63. 2005..High CSF levels may be useful in the diagnosis of ADC in subjects with advanced immunosuppression in whom CMV encephalitis has been ruled out, though this issue requires further study... - CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegenerationSahra Abdulle
Department of Infectious Diseases, The Sahlgrenska Academy at Goteborg University, Gothenburg, Sweden
J Neurol 254:1026-32. 2007..The effect of highly active antiretroviral treatment (HAART) was studied by repeated CSF sampling in four of the ADC patients initiating treatment... - Timed Gait test: normative data for the assessment of the AIDS dementia complexKevin R Robertson
AIDS Neurological Center and Department of Neurology, School of Medicine, University of North Carolina at Chapel Hill, NC 27599 7025, USA
J Clin Exp Neuropsychol 28:1053-64. 2006..These normative data should prove useful in both recognition of ADC and treatment response. Given its minimal training requirements, the Timed Gait would have utility in resource limited settings... - Determination of the underlying cause of death in three multicenter international HIV clinical trialsAlan R Lifson
University of Minnesota, Minneapolis, Minnesota 55454 1015, USA
HIV Clin Trials 9:177-85. 2008..Describe processes and challenges for an Endpoint Review Committee (ERC) in determining and adjudicating underlying causes of death in HIV clinical trials... - Editorial comment: AIDS dementia complex in the current eraRichard W Price
AIDS Read 16:630-1. 2006 - Editorial comment: déjà vu--neurologic complications of HIV infection in the expanding epidemicRichard W Price
AIDS Read 15:144. 2005 - Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system diseaseNicolai Sidenius
Molecular Genetics Unit, DIBIT, San Raffaele Scientific Institute, Via Olgettina 58, 20132 Milan, Italy
J Neuroimmunol 157:133-9. 2004..Additionally, these findings are consistent with a model in which overexpression of uPAR and overproduction of its soluble form may promote HIV replication via binding and removal of uPA from cell surface... - Editorial comment: diagnosis of focal brain lesions--old lessons retaughtRichard W Price
AIDS Read 13:553. 2003 - Neurological complications of HIV infection and AIDS: current and future perspectivesPaola Cinque
Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
J Neurovirol 11:1-5. 2005 - Screening for the AIDS dementia complexRichard W Price
AIDS Read 12:32-3. 2002
Research Grants
- Treatment&Pathogenesis of Cerebrospinal Fluid HIV InfectRichard Price; Fiscal Year: 2004....
- CSF HIV & LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPYRichard Price; Fiscal Year: 2004....
- CSF Molecular Marker Study ConsortiumRichard Price; Fiscal Year: 2006..abstract_text> ..
- CSF & Lymphocyte Dynamics in HIV InfectionRichard Price; Fiscal Year: 2007..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..
- CSF & Lymphocyte Dynamics in HIV InfectionRichard Price; Fiscal Year: 2009..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..
- CFS FLUID AFTER RETROVIRAL TREATMENT FOR HIVRichard Price; Fiscal Year: 2000..Antiviral effects will be correlated with the kinetics of drug entry into the CSF. ..
- CSF & Lymphocyte Dynamics in HIV InfectionRichard W Price; Fiscal Year: 2010..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..